HIV associated nephropathy natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{HIV associated nephropathy}} | {{HIV associated nephropathy}} | ||
{{CMG}}{{APM}};{{AE}}{{KW}} | {{CMG}}{{APM}};{{AE}}{{KW}}{{SHA}} | ||
==Overview== | ==Overview== | ||
Line 20: | Line 20: | ||
* Before the advent of cART therapy, the prognosis of HIV-associated nephropathy was fatal. The mortality rate during this time was 100% within 6 months.<ref name="pmid18588500" /> | * Before the advent of cART therapy, the prognosis of HIV-associated nephropathy was fatal. The mortality rate during this time was 100% within 6 months.<ref name="pmid18588500" /> | ||
* Today, the prognosis of HIVAN with the availability of cART therapy still remains grim,<ref name="pmid18588500" /> however, treatment with cART has increased renal survival rate. | * Today, the prognosis of HIVAN with the availability of cART therapy still remains grim,<ref name="pmid18588500" /> however, treatment with cART has increased renal survival rate.18190325 | ||
* Early diagnosis and Immediate treatment has shown better outcome.<ref name="pmid18588500" /> | * Early diagnosis and Immediate treatment has shown better outcome.<ref name="pmid18588500" /> | ||
* Treatment with cART has shown 60% reduction in the developement of HIVAN.<ref name="pmid18588500" /> | * Treatment with cART has shown 60% reduction in the developement of HIVAN.<ref name="pmid18588500" /> | ||
* Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.<ref name="pmid18588500" /> | * Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.<ref name="pmid18588500" /> | ||
* The current first and second year survival rate of HIV-associated nephropathy is estimated to be around 63% and 43% respectively, with the use of HAART therapy. | * The current first and second year survival rate of HIV-associated nephropathy is estimated to be around 63% and 43% respectively, with the use of HAART therapy.<ref name="pmid16271919">{{cite journal| author=Atta MG, Choi MJ, Longenecker JC, Haymart M, Wu J, Nagajothi N | display-authors=etal| title=Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. | journal=Am J Med | year= 2005 | volume= 118 | issue= 11 | pages= 1288 | pmid=16271919 | doi=10.1016/j.amjmed.2005.05.027 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16271919 }} </ref> | ||
'''The following are favorable prognostic factors:''' | '''The following are favorable prognostic factors:''' |
Revision as of 13:11, 28 June 2020
HIV associated nephropathy Microchapters |
Differentiating HIV associated nephropathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
HIV associated nephropathy natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of HIV associated nephropathy natural history, complications and prognosis |
FDA on HIV associated nephropathy natural history, complications and prognosis |
CDC on HIV associated nephropathy natural history, complications and prognosis |
HIV associated nephropathy natural history, complications and prognosis in the news |
Blogs on HIV associated nephropathy natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]Shakiba Hassanzadeh, MD[4]
Overview
HIV-associated nephropathy (HIVAN) will progress to end-stage renal disease (ESRD) in a few weeks to months without treatment. However, early diagnosis and treatment has shown better outcome.
Natural History
- If left untreated, HIV-associated nephropathy (HIVAN) will progress to end-stage renal disease (ESRD) in a few weeks to months.[1]
- Treatment with cART has shown 60% reduction in the developement of HIVAN.[1]
- Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.[1]
- Early diagnosis and Immediate treatment has shown better outcome.[1]
Complications
Possible complications that are associated with HIV-associated nephropathy include:
- End-stage renal disease (ESRD)[1]
Prognosis
- Before the advent of cART therapy, the prognosis of HIV-associated nephropathy was fatal. The mortality rate during this time was 100% within 6 months.[1]
- Today, the prognosis of HIVAN with the availability of cART therapy still remains grim,[1] however, treatment with cART has increased renal survival rate.18190325
- Early diagnosis and Immediate treatment has shown better outcome.[1]
- Treatment with cART has shown 60% reduction in the developement of HIVAN.[1]
- Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.[1]
- The current first and second year survival rate of HIV-associated nephropathy is estimated to be around 63% and 43% respectively, with the use of HAART therapy.[2]
The following are favorable prognostic factors:
- Patients on HAART therapy
- Patients with low-grade proteinuria
- Patients who have a suppressed HIV-1 viral load
- Patients who express a normal renal echogenicity
- Patients with CD4 levels that between 200 and 500 cells/mm3
- Patients who have higher estimated glomerular filtration rates
The following are poor prognostics factors:
- Patients not receiving HAART therapy
- Patients with high-grade proteinuria
- Patients who have under suppressed HIV-1 viral load
- Patients who express a large renal echogenicity
- Patients who have CD4 levels that are below 200 cells/mm3
- Patients who have lower estimated glomerular filtration rates
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Atta MG, Lucas GM, Fine DM (2008). "HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management". Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.
- ↑ Atta MG, Choi MJ, Longenecker JC, Haymart M, Wu J, Nagajothi N; et al. (2005). "Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy". Am J Med. 118 (11): 1288. doi:10.1016/j.amjmed.2005.05.027. PMID 16271919.